Trial: 202111024

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Phase

I

Principal Investigator

Morgensztern, Daniel

Disease Site

Breast; Lung; Multiple Myeloma; Ovary; Pancreas

Learn more about this study at: clinicaltrials.gov